Ocugen, Inc. · NASDAQ:OCGN
Ocugen — Investor Presentation (March 2022)
15 slides from Ocugen's investor presentation, Mar 11, 2022
Slide 1: Ocugen: a biotech company discovering, developing and commercializing therapies
…a biotech company focused on discovering, developing, and commercializing therapies that improve health and offer hope for people and global communities
Slide 2: Forward Looking Statement
2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “conti
Slide 3: We're Here to Make an Impact Through Courageous Innovation
Pioneering a breakthrough modifier gene therapy for several genetic forms of vision impairment Innovating a novel biologic to treat eye diseases that can lead to vision loss for millions of people Co-developing a COVID-19 vaccine 3 We’re Here to Make an Impact Through Courageous Innovation Mission A
Slide 4: Pipeline Overview
Pipeline Overview * Based on Bharat Biotech-sponsored clinical trials in India ** No approved therapies exist https://www.aao.org/eye-health/diseases/retinitis-pigmentosa-treatment | https://www.aao.org/eye-health/diseases/amd-treatment Asset/Program Indication Status Vaccine COVAXIN™ (BBV152) Whole
Slide 5: COVAXIN (BBV152) A Whole-Virion Inactivated COVID-19 Vaccine Candidate
5 COVAXIN™ (BBV152) A Whole-Virion Inactivated COVID-19 Vaccine Candidate Licensed from Bharat Biotech (BBIL) for the US and Canadian Markets
Slide 6: Why COVAXIN (BBV152)?
Why COVAXIN™ (BBV152)? Designed to augment our North American arsenal of vaccines against COVID-19 6 • Adult and pediatric phase 2/3 data suggest both humoral & cellular responses generated against multiple viral proteins • Data support that the vaccine induces a Th1 response (cell-mediated immunity
Slide 7: Phase 3 Clinical Trial Highlights
Phase 3 Clinical Trial Highlights 7 77.8% 93.4% 65.2% Overall efficacy Efficacy vs severe disease Efficacy vs B.1.617.2 (Delta) Serious Adverse Events Adverse Events Placebo Arm Adverse Events COVAXIN™ Arm 12.4% <0.5% n = 25,800 participants Participants recruited between November 2020 and January 2
Slide 8: Pathway for COVAXIN (BBV152) in 2022
Pathway for COVAXIN™ (BBV152) in 2022 NCT: 05258669 OCU-002 A Phase 2/3, Observer-Blind, Immuno-bridging, and Broadening Study of a Whole, Inactivated Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Vaccine (BBV152) in Healthy Adults Study Type Interventional (Clinical Trial) Estimated En
Slide 9: Modifier Gene Therapy Platform
9 MODIFIER GENE THERAPY PLATFORM Breakthrough technology designed to address many rare diseases as well as complex diseases that affect millions
Slide 10: Our Focus: Nuclear Hormone Receptor Genes (NHRs)
Our Focus: Nuclear Hormone Receptor Genes (NHRs) 10 *References: https://pubmed.ncbi.nlm.nih.gov/28556246/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409218/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339951/ | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0183526 Photore
Slide 11: Our Vision: Modifier Gene Therapy vs Traditional Gene Augmentation
Our Vision: Modifier Gene Therapy vs Traditional Gene Augmentation 11 Normal gene X Gene Augmentation: Transfer functional version of a non-functional gene into the target cells. Modifier Gene Therapy: Designed to introduce a functional gene to modify the expression of many genes, gene-networks and
Slide 12: Our Proof of Principle: Published in Nature Gene Therapy
Our Proof of Principle: Published in Nature Gene Therapy 12 https://www.nature.com/articles/s41434-020-0134-z Important milestone for development of therapy; demonstrated proof of principle Protection elicited in multiple animal models of degeneration caused by different mutations Potential to repre
Slide 13: OCU400 – Pathway to Phase 1/2 clinical trials
OCU400 – Pathway to Phase 3 clinical trials OCU400 A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 (Nuclear Receptor Subfamily 2 Group E Member 3) and RHO (Rhodopsin) Mutations Study Type Interventional (Clinical Trial) Estimated Enrollmen
Slide 14: Forward Momentum for Ocugen
Phase 1/2 clinical trial studying OCU400 for the treatment of retinitis pigmentosa resulting from genetic mutations of NR2E3 and RHO now enrolling Successfully completed manufacturing at commercial scale (200L) at CanSinoBio to support clinical studies Expanded manufacturing agreement with CanSinoBi
Slide 15: Thank you!
eS %, ocugen. Thank you! ———